Steven Prestrelski - Jan 3, 2022 Form 4 Insider Report for Xeris Biopharma Holdings, Inc. (XERS)

Role
Chief Scientific Officer
Signature
/s/ Beth Hecht, as Attorney-in-Fact
Stock symbol
XERS
Transactions as of
Jan 3, 2022
Transactions value $
$0
Form type
4
Date filed
1/5/2022, 05:15 PM
Previous filing
Oct 5, 2021
Next filing
Feb 24, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction XERS Common Stock Award $0 +75K +15.16% $0.00 570K Jan 3, 2022 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These shares were acquired pursuant to a restricted stock unit award under the Company's 2018 Stock Option and Incentive Plan. Each restricted stock represents a contingent right to receive one share of the Company's common stock. These shares shall vest in equal annual installments over three years.